Drug Name: Rezlidhia
Active Ingredient: olutasidenib
Indications: To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation
Approval Date: 12/1/2022
Company: Forma Therapeutics, Inc (A Novo Nordisk company)
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf